- Home
- OVV vs RVMD Comparison
OVV vs RVMD Comparison
Compare OVV & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVV
- RVMD
- Stock Information
- Founded
- OVV 2020
- RVMD 2014
- Country
- OVV United States
- RVMD United States
- Employees
- OVV N/A
- RVMD N/A
- Industry
- OVV Oil & Gas Production
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OVV Energy
- RVMD Health Care
- Exchange
- OVV Nasdaq
- RVMD Nasdaq
- Market Cap
- OVV 10.8B
- RVMD 8.7B
- IPO Year
- OVV N/A
- RVMD 2020
- Fundamental
- Price
- OVV $37.68
- RVMD $44.06
- Analyst Decision
- OVV Buy
- RVMD Strong Buy
- Analyst Count
- OVV 17
- RVMD 12
- Target Price
- OVV $56.19
- RVMD $64.67
- AVG Volume (30 Days)
- OVV 3.1M
- RVMD 2.2M
- Earning Date
- OVV 11-07-2024
- RVMD 11-06-2024
- Dividend Yield
- OVV 3.18%
- RVMD N/A
- EPS Growth
- OVV N/A
- RVMD N/A
- EPS
- OVV 7.54
- RVMD N/A
- Revenue
- OVV $9,562,000,000.00
- RVMD $742,000.00
- Revenue This Year
- OVV N/A
- RVMD N/A
- Revenue Next Year
- OVV N/A
- RVMD $1,855.42
- P/E Ratio
- OVV $5.01
- RVMD N/A
- Revenue Growth
- OVV N/A
- RVMD N/A
- 52 Week Low
- OVV $36.91
- RVMD $25.93
- 52 Week High
- OVV $55.95
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- OVV 29.90
- RVMD 32.07
- Support Level
- OVV $41.10
- RVMD $44.50
- Resistance Level
- OVV $39.39
- RVMD $46.15
- Average True Range (ATR)
- OVV 1.09
- RVMD 1.89
- MACD
- OVV -0.64
- RVMD -0.58
- Stochastic Oscillator
- OVV 4.56
- RVMD 19.95
About OVV Ovintiv Inc. (DE)
Ovintiv is a North American oil and natural gas exploration and production company. It focuses on the exploration and development of oil, NGLs, and natural gas reserves. The company has three segments: USA Operations, Canadian Operations, and Market Optimization.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.